[3]Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar. Cell Rep Med. 2024;5(6):101575. [4]Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOP...
a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer. 2016;139(10):2336-2342.
Concordantly to the knowledge of the HER2+ breast cancer heterogeneity as well as new drugs, novel predictive biomarkers of response to anti-HER2 treatments are always raised helping to define target to overcome resistance. Cotargeting HER2 and hormone receptors is the most well known mechanism to ...
[3]Kang Z, Jin Y, Yu H,et al. Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis. BMC Cancer. 2024 Jun 8;24(1):708. 审批编号：CN-147873 有效期至：2025-11-21本材料...
Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions. This is a modal window. This video is either unavailable or not supported in this browser Error ...
Yap YS, Cornelio GH, Devi BC, et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012;107(7):1075-1082. Renfrow JJ, Lesser GJ. Molecular subtyping of brain metastases and implications for therapy. Curr Tr...
0:08 | Many of the treatments that we use in the first-line setting for patients with metastatic HER2+ positive breast cancer are based off of the data from the CLEOPATRA trial, which was published in the New England Journal of Medicine a number of years ago. It involved using a taxane...
7.Ma X, Li Y, Li L, Gao C, Liu D, Li H, Zhao Z, Zhao B. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases. Ann Med. 2022 Dec;54(1):3085-3095. 8.Wang H, Liu Q...
1. Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar. Cell Reports Medcine. VOLUME 5, ISSUE 6, 101575, JUNE 18, 2024. 2. 乳腺癌疫苗的现状与展望. 实用医学杂志. 2022年,38(20),2505-250...
The phase III TH3RESA trial randomized ∼600 patients with advanced HER2-positive breast cancer, previously treated with at least two HER2-directed therapies (including trastuzumab and lapatinib) in a 2 : 1 ratio to T-DM1 or physician’s choice of treatment (HER2-targeted regimens for ...